The latest Investing Matters Podcast with Jean Roche, Co-Manager of Schroder UK Mid Cap Investment Trust has just been released. Listen here.
Its so annoying when they say it was refused.
It makes one wonder how quick it would go through if it was a covid 19 drug.
The reason why MTFB could not take the drug further was simply because they did not have the injection of cash which was needed to progress to the next stage, the drug was not refused by the FDA, they just required more data which involved more cash being thrown at it and I bet my bottom dollar another company will pop up and all the Bods will be part of that company. DYOR
Spot on with regards to the dilution, do you think this SP has legs
IMO, Looking at costains fundamental data, with such a low PE ratio, this share is a bargain at a £1.
Hi everyone, just been reading the BB and totally understand people's frustration on how this as been handled by the BOD, surely costain now are in a much better position in the market with a very healthy bank balance to reassure their existing and new clients, let's hope either delayed or new contracts will be announced soon, why else would they raise this money.
Midas chill out buddy, they are just trying to wind you up, with regards to the modest buys, I think that an institutional invester is buying up small chunks at a low price for Chris Wardhaugh and co in order to build up their stake of maybe 50% and then the rns will come out.
But £7m of debt is nothing to a pharma company or Hercules, I honestly think there is going to be a big suprise here and this share will go north up into the hills and all us long term holders will be standing on the top of them hills looking South at the coastline watching them donkeys going up and down the same old beach. "Silly Donkeys"
Midas you seem to have your finger on the pulse, so why the board change ?
And Chris Wardhaugh was made a non executive director exactly the same title has Graham Lumsden holds, not to put anyone's nose out of joint.
Hi Latino, I am new to this BB and i am a LTH of MTFB, I totally agree with your last post, I personally think that the reason for Chris Wardhaugh joining the bod, is to overlook the RTO, to ensure it goes in the right direction to suite the plans they have , with either a new drug or advancing iclaprim forward IMHO.
Hi jackdaw99, very good post thanks for the info.
Not that I am a lung specialists, at this present moment we are all aware that there is a rapid race on to find a suitable drug to treat that horrid disease Covid-19, which we all know is a lung disease, if a new drug is developed it would have to go through the trial process, which we all know is very costly and time consuming, and what does motif bio/Hercules have, a drug called iclaprim which is for lung infections and yes lots of cash has been thrown at it and yes its been through the lenghty trial process, makes one think ?
Would just like to add that basic rule on stocks "Never buy on speculation" but I have a sneaky feeling that another drug company will pop up out of nowhere who have big plans, because if an RTO takes place, it would be easiest and quickest way to float on the market without having to through an IPO etc, and officemanager I think the big buy of £197k was someone who may knows what exactly is going on.
Re: RTO. I totally agree with juyamah and is excellent research, does anyone think another drug company would be interested in MTFB.
Cheers juyamah, good to chat with people with an excellent knowledge of this situation we are in
Hasiba, top man excellent link, now it makes sense why someone new is on board, to overlook the RTO.
Hi everyone, am new to this board and am a LTH in Motif, I agree with hasiba's post but on looking at juyamah's post is this the case with regards to a RTO, would be very appreciative if someone could enlighten my knowledge.